Capital Fund Management (CFM)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Capital Fund Management (CFM)’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-20,591	Closed	-$4.97M	–	2442
2025 Q2	$4.97M	Buy	+20,591	New	+$4.87M	0.01%	1143
2024 Q2	–	Sell	-11,188	Closed	-$3.87M	–	1882
2024 Q1	$3.87M	Buy	+11,188	New	+$3.68M	0.01%	1172
2021 Q1	–	Sell	-24,407	Closed	-$14.2M	–	1277
2020 Q4	$14.2M	Buy	+24,407	New	+$13.9M	0.13%	182
2019 Q4	–	Sell	-1,561	Closed	-$519K	–	1819
2019 Q3	$519K	Buy	+1,561	New	+$509K	﹤0.01%	1244
2018 Q4	–	Sell	-5,200	Closed	-$1.63M	–	1849
2018 Q3	$1.63M	Buy	+5,200	New	+$1.61M	0.01%	1200
2014 Q3	–	Sell	-3,100	Closed	-$371K	–	1524
2014 Q2	$371K	Buy	+3,100	New	+$379K	﹤0.01%	1341

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Capital Fund Management (CFM)'s BIO Position: Q3 2025 in Review

Capital Fund Management (CFM) sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2025, closing a stake of 20,591 shares — an estimated $4.97M sold.

Capital Fund Management (CFM) first reported a position in BIO in Q2 2014 and held it in 6 quarters. The position peaked at $14.2M in Q4 2020. 397 funds tracked by Wall St. Rank hold BIO as of Q3 2025.

Capital Fund Management (CFM) reported no remaining Bio-Rad Laboratories Class A position as of Q3 2025 after selling out during the quarter.
Capital Fund Management (CFM) sold 20,591 Bio-Rad Laboratories Class A shares in Q3 2025, an estimated $4.97M.
Capital Fund Management (CFM) first reported a position in Bio-Rad Laboratories Class A in Q2 2014 and held it in 6 quarters.
Capital Fund Management (CFM)'s Bio-Rad Laboratories Class A position peaked at $14.2M in Q4 2020.
397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2025.

Based on Capital Fund Management (CFM)'s 13F filing for Q3 2025, filed 13 Nov 2025.